Aurinia Pharmaceuticals Inc (AUPH)
NASDAQ · Manufacturing · Pharmaceutical preparations
AUPH price, last 12 months
Key stats
- Previous close
- $15.13
- Open
- $15.09
- Day range
- $14.81 – $15.22
- 52-week range
- $13.52 – $19.25
- Volume
- 968.6K
- Avg volume (20 days)
- 942.4K
- Market cap
- $2.1B
Performance
Technicals and fundamentals
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.1B